List of Yupelri drug patents
Yupelri is owned by Mylan Ireland Ltd.
Yupelri contains Revefenacin.
Yupelri has a total of 17 drug patents out of which 0 drug patents have expired.
Yupelri was authorised for market use on 09 November, 2018.
Yupelri is available in solution;inhalation dosage forms.
Yupelri can be used as for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd).
Drug patent challenges can be filed against Yupelri from November, 2022.
The generics of Yupelri are possible to be released after 23 October, 2039.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7585879 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 years from now) | |
| US7910608 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 years from now) | |
| US7288657 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Dec, 2025
(2 years from now) | |
| US9765028 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(7 years from now) | |
| US10550081 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(7 years from now) | |
| US8541451 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Aug, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7491736 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 years from now) | |
| US7521041 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 years from now) | |
| US10106503 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 years from now) | |
| US10343995 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 years from now) | |
| US8053448 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 years from now) | |
| US8273894 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 years from now) | |
| US11247969 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 years from now) | |
| US8034946 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 years from now) | |
| US7550595 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Mar, 2025
(2 years from now) | |
| US11008289 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Jul, 2030
(7 years from now) | |
| US11484531 | MYLAN IRELAND LTD | NA |
Oct, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 9, 2023 |
Drugs and Companies using REVEFENACIN ingredient
NCE-1 date: November, 2022
Market Authorisation Date: 09 November, 2018
Treatment: For the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: SOLUTION;INHALATION
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic